EP Patent

EP4114365A1 — Pharmaceutical composition comprising sglt2 inhibitor

Assigned to KRKA dd · Expires 2023-01-11 · 3y expired

What this patent protects

Pharmaceutical compositions are provided which contain at least one SGLT2 inhibitor. Specifically, the present invention provides pharmaceutical compositions containing one or more SGLT2 inhibitor such as dapagliflozin, optionally in a combination with one or more other active su…

USPTO Abstract

Pharmaceutical compositions are provided which contain at least one SGLT2 inhibitor. Specifically, the present invention provides pharmaceutical compositions containing one or more SGLT2 inhibitor such as dapagliflozin, optionally in a combination with one or more other active substances.

Drugs covered by this patent

Patent Metadata

Patent number
EP4114365A1
Jurisdiction
EP
Classification
—
Expires
2023-01-11
Drug substance claim
No
Drug product claim
No
Assignee
KRKA dd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.